Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19

The severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), and the resulting illness, COVID-19, developed in Wuhan, China in late 2019 (1). Within months, COVID-19 became a worldwide pandemic, with millions cases reported (2). Nephrologists have been front-and-center, caring for infected dialysis patients while also treating hospitalized COVID-19 patients with acute kidney injury…

Read the full article here

Related Articles